Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea

被引:50
作者
Konno, Ryo [1 ]
Shin, Hai-Rim [2 ,3 ]
Kim, Young-Tak [4 ]
Song, Yong Sang [5 ]
Sasagawa, Toshiyuki [6 ]
Inoue, Masaki [7 ]
Park, Jong-Sup [8 ]
机构
[1] Jichi Med Univ, Dept Gynecol, Saitama Med Ctr, Omiya, Saitama, Japan
[2] Natl Canc Ctr, Natl Canc Control Res Inst, Canc Prevent Div, Goyang, South Korea
[3] Int Agcy Res Canc, Biostat & Epidemiol Cluster, Data Anal & Interpretat Grp, F-69372 Lyon, France
[4] Univ Ulsan, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[5] Seoul Natl Univ, Dept Obstet & Gynecol, Seoul, South Korea
[6] Kanazawa Univ, Div Hlth Sci, Fac Med, Kanazawa, Ishikawa, Japan
[7] Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan
[8] Catholic Univ, Kangnam St Marys Hosp, Div Gynecol Oncol, Seoul, South Korea
关键词
Japan; Korea; HPV; Cervical cancer; Screening; HPV vaccine; Asia Pacific;
D O I
10.1016/j.vaccine.2008.05.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cervical cancer is a common cancer among women in Japan and Korea. Implementation of national cervical cancer screening programs has led to a reduction in the incidence of cervical cancer in both countries. However, over the past decade, there has been a recent marked increase in cervical cancer incidence among young women in Japan. Human papillomavirus (HPV) is found in the majority of cervical cancers, and HPV-16 and 18 are the two most common types. The next most frequent HPV types in cervical cancer are 52, 58 and 33 for Japan and 52, 58, and 33 for Korea, varying slightly when compared to the worldwide distribution. Screening coverage for both countries remains a challenge. Current coverage is reported at 24% in Japan, with the lowest coverage in young Japanese women, and 41% in Korea. Cytology remains the predominant screening method. HPV DNA testing is widely used to triage women with abnormal cytology in Korea. HPV vaccines have been licensed in Korea, but not yet in Japan. In both countries cost is a substantial impediment to implementation and no national programs are currently planned or in place. Therefore, increased disease awareness and utilization of screening is the first priority for controlling cervical cancer. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:M30 / M42
页数:13
相关论文
共 59 条
[21]  
KIM SG, 2007, EUROPEAN J CANC CARE, P1
[22]  
KIM SJ, 2001, KOREAN J OBSTET GYNE, V44, P911
[23]  
Kim YB, 2003, KOREAN J GYNECOL ONC, V46, P789
[24]   Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV 16 minor capsid protein L2 surface region [J].
Kondo, Kazunari ;
Ishii, Yoshiyuki ;
Ochi, Hiroyuki ;
Matsumoto, Tamae ;
Yoshikawa, Hiroyuki ;
Kanda, Tadahito .
VIROLOGY, 2007, 358 (02) :266-272
[25]  
*KOR CTR DIS CONTR, 2006, 2 ONL SURV HLTH BEH
[26]   Human papillomavirus genotyping using HPV DNA chip analysis in Korean women [J].
Lee, H. S. ;
Kim, K. M. ;
Kim, S. M. ;
Choi, Y. D. ;
Nam, J. H. ;
Park, C. S. ;
Choi, H. S. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) :497-501
[27]  
Lee JH, 2006, KOREAN J GYNECOL ONC, V49, P858
[28]  
Maehama Toshiyuki, 2005, Infect Dis Obstet Gynecol, V13, P77, DOI 10.1080/10647440400028151
[29]  
Matsumoto K, 2000, J MED VIROL, V60, P200, DOI 10.1002/(SICI)1096-9071(200002)60:2<200::AID-JMV15>3.0.CO
[30]  
2-G